利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.038 秒)

    Substituted amides
    1.
    发明申请
    Substituted amides 有权

    公开(公告)号：US20060106071A1

    公开(公告)日：2006-05-18

    申请号：US10538395

    申请日：2003-12-15

    申请人： Linus Lin ,  William Hagmann ,  Sanjeev Kumar ,  Wenji Yin ,  George Doss

    发明人： Linus Lin ,  William Hagmann ,  Sanjeev Kumar ,  Wenji Yin ,  George Doss

    IPC分类号： A61K31/44 ,  A61K31/277 ,  C07D213/63 ,  C07C255/50

    CPC分类号： C07D213/64 ,  C07C255/60 ,  C07C275/24 ,  C07C2601/04

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    Substituted sulfonamides
    7.
    发明申请
    Substituted sulfonamides 审中-公开
    取代磺酰胺

    公开(公告)号：US20070105914A1

    公开(公告)日：2007-05-10

    申请号：US10571842

    申请日：2004-09-14

    申请人： Helen Armstrong ,  Linda Chang ,  Ravindra Guthikonda ,  William Hagmann ,  Linus Lin ,  Shrenik Shah

    发明人： Helen Armstrong ,  Linda Chang ,  Ravindra Guthikonda ,  William Hagmann ,  Linus Lin ,  Shrenik Shah

    IPC分类号： A61K31/44 ,  A61K31/277 ,  A61K31/18

    CPC分类号： C07C311/06 ,  A61K31/18 ,  A61K31/277 ,  A61K31/44 ,  C07C311/03 ,  C07C311/13 ,  C07C311/16 ,  C07C311/17 ,  C07C311/19 ,  C07C311/29 ,  C07D209/08

    摘要： The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 本发明的取代磺酰胺是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。该化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘， 便秘，慢性肠假性梗阻和肝硬化。

    Acyclic Hydrazides as Cannabinoid Receptor Modulators
    10.
    发明申请
    Acyclic Hydrazides as Cannabinoid Receptor Modulators 审中-公开
    非环状酰肼作为大麻素受体调节剂

    公开(公告)号：US20080076805A1

    公开(公告)日：2008-03-27

    申请号：US11661834

    申请日：2005-10-03

    申请人： Linus Lin ,  Ping Liu

    发明人： Linus Lin ,  Ping Liu

    IPC分类号： A61K31/4412 ,  A61K31/165 ,  A61P25/00 ,  C07C243/12 ,  C07D213/63

    CPC分类号： C07C255/66 ,  C07C243/28 ,  C07C243/32 ,  C07C243/36 ,  C07C2601/08 ,  C07D213/64

    摘要： The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 本发明的无环酰肼是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍（包括戒烟），治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。